POLN: A Potential Drug Target for Cancer (G353497)

Target Name: POLN

NCBI ID: G353497

POLN

POLN: A Potential Drug Target for Cancer

POLN, or DNA polymerase N, is a key enzyme in the DNA replication process. It is responsible for creating a new DNA strand in the double helix that is a copy of the original DNA template. POLN is a protein that is expressed in all living cells and is essential for cell growth and replication. However, it is also known to be involved in the development and progression of many diseases, including cancer. As a result, POLN has become a focus of interest for researchers as a potential drug target or biomarker.

The DNA replication process is critical for the growth and development of all living organisms. Polynucleotide synthesis is the first step in the replication process and it is a critical step for the efficient growth of the cell. POLN is the enzyme that synthesizes the new DNA strand that is replicated in the double helix. It uses a small set of primers to create a new DNA strand that is an exact copy of the original template.

POLN is a protein that is expressed in most cells of the human body and it plays a critical role in the replication of DNA in all cells. It is a transcription factor that binds to specific DNA sequences and activates the DNA replication machinery. It is also involved in the regulation of gene expression and it is a key factor in the development and progression of many diseases, including cancer.

One of the key features of POLN is its role in cancer development. It has been shown to be involved in the development and progression of many types of cancer, including breast, ovarian, and prostate cancers. the regulation of cell cycle progression and it is a key factor in the regulation of apoptosis, which is a normal mechanism for cell death.

Another feature of POLN is its potential as a drug target. Polynucleotide synthesis is a critical step in the replication process and it is a target for many drugs that are used to treat cancer. For example, one of the most well-known drugs used to treat cancer is taxol, which is a taxane-based drug that inhibits the activity of POLN. Taxol is used to treat breast and ovarian cancers and it has been shown to be effective in treating these types of cancers.

In addition to its potential as a drug target, POLN is also being studied as a biomarker for cancer. The expression of POLN is often reduced in the cells of cancer and it has been shown to be a reliable biomarker for the diagnosis and prognosis of many types of cancer. It is also been shown to be a biomarker for the response to anti-cancer drugs and it has been used to predict the outcome of chemotherapy.

POLN is also involved in the regulation of gene expression and it is a key factor in the development and progression of many diseases. For example, it is involved in the regulation of the development and progression of cancer and it is a key factor in the regulation of apoptosis. It is also involved in the regulation of cell cycle progression and it is a key factor in the regulation of mitosis.

In conclusion, POLN is a key enzyme that is involved in the DNA replication process and it is a critical factor in the growth and development of all living organisms. It is also involved in the development and progression of many diseases, including cancer. As a As a result, it has become a focus of interest for researchers as a potential drug target or biomarker. Further studies are needed to fully understand the role of POLN in disease and to develop effective treatments.

Protein Name: DNA Polymerase Nu

Functions: DNA polymerase with very low fidelity that catalyzes considerable misincorporation by inserting dTTP opposite a G template, and dGTP opposite a T template (PubMed:16787914, PubMed:17118716). Is the least accurate of the DNA polymerase A family (i.e. POLG, POLN and POLQ) (PubMed:17118716). Can perform accurate translesion DNA synthesis (TLS) past a 5S-thymine glycol. Can perform efficient strand displacement past a nick or a gap and gives rise to an amount of product similar to that on non-damaged template. Has no exonuclease activity (PubMed:16787914). Error-prone DNA polymerase that preferentially misincorporates dT regardless of template sequence (PubMed:25775266). May play a role in TLS during interstrand cross-link (ICL) repair (PubMed:19908865). May be involved in TLS when genomic replication is blocked by extremely large major groove DNA lesions. May function in the bypass of some DNA-protein and DNA-DNA cross-links. May have a role in cellular tolerance to DNA cross-linking agents (PubMed:20102227). Involved in the repair of DNA cross-links and double-strand break (DSB) resistance. Participates in FANCD2-mediated repair. Forms a complex with HELQ helicase that participates in homologous recombination (HR) repair and is essential for cellular protection against DNA cross-links (PubMed:19995904)

The "POLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets